Hypertrophic lichen planus

Summary

Hypertrophic lichen planus (MONDO:0021377) is a disease. A subtype of lichen planus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hypertrophic lichen planus
Mondo ID	MONDO:0021377
ICD-10-CM	L43.0
ICD-11	1096967508
NCIT	C34779
SNOMED CT	68266006
UMLS	C0023649
MedGen	9756
Is cancer (heuristic)	no

Also known as: hypertrophic lichen planus · Lichen planus hypertrophicus

Disease family

This is a subtype of lichen planus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › lichen planus › hypertrophic lichen planus

Related subtypes (10): lichen planus, familial, linear lichen planus, actinic lichen planus, annular atrophic lichen planus, annular lichen planus, atrophic lichen planus, lichen planus pigmentosus, lichen planus pemphigoides, bullous lichen planus, lichen planus, oral

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.